MedTrace Logo

Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients

NCT04257838 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-02-06

No results posted yet for this study

Summary

The aim of this study is to establish the Piperacillin-Tazobactam and Meropenem Plasmatic Levels to know if it´s necessary to make some adjustment in the recommended dose regimen.

Conditions

Interventions

DRUG

Piperacillin/tazobactam or Meropenem

The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected: 1. Just before the antibiotic infusion (T0) 2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours. A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.

Sponsors & Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • José Garnacho Montero · Hospital Universitario Virgen Macarena

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-15
Primary Completion
2020-12-15
Completion
2021-03-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04257838 on ClinicalTrials.gov